Abdomen

Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment

Tuesday, June 2, 2020 - 7:00am

Gelesis , a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, announced today that it has received approval to market Plenity, a novel weight loss treatment, in Europe.

Key Points: 
  • Gelesis , a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, announced today that it has received approval to market Plenity, a novel weight loss treatment, in Europe.
  • The CE mark will further broaden access to a weight loss option that can impact tens of millions of patients globally.
  • Gelesis will now be able to market Plenity throughout the EEA and in other countries that recognize the CE mark.
  • We believe Plenity is a highly differentiated option for this serious public health issue, said Yishai Zohar, founder and chief executive officer of Gelesis.

Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

Wednesday, May 27, 2020 - 12:00pm

IAP administration, starting at 10 months of age, slowed the microbiome changes, gut-barrier dysfunction, and gastrointestinal and systemic inflammation that normally accompany aging.

Key Points: 
  • IAP administration, starting at 10 months of age, slowed the microbiome changes, gut-barrier dysfunction, and gastrointestinal and systemic inflammation that normally accompany aging.
  • Additionally, the IAP administration resulted in improved metabolic profiles in the aged mice, diminished frailty, and extended lifespan.
  • Under the terms of the agreement, Synthetic Biologics is granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging.
  • Synthetic Biologics is currently developing SYN-020 to reduce acute intestinal side effects associated with radiation therapy in cancer patients.

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules

Monday, May 18, 2020 - 5:33am

Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.

Key Points: 
  • Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.
  • The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product.
  • In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Global Gastrointestinal Stents Market Outlook 2020-2025: Biliary, Duodenal, Colonic, Pancreatic and Esophageal Stents

Wednesday, May 13, 2020 - 10:00pm

The global gastrointestinal stents market reached a value of US$ 386.3 million in 2019.

Key Points: 
  • The global gastrointestinal stents market reached a value of US$ 386.3 million in 2019.
  • Furthermore, an increasing geriatric population suffering from gastrointestinal diseases, such as bowel ailments, diverticulosis and gastrointestinal malignancies, is also providing a boost to the market growth.
  • How has the global gastrointestinal stents market performed so far and how will it perform in the coming years?
  • What is the structure of the global gastrointestinal stents market and who are the key players?

Debbie's Dream Foundation: Curing Stomach Cancer Announces the Launch of New Dream Makers Miracle Fund for Patients and Their Families

Friday, May 8, 2020 - 1:32pm

PLANTATION,Fla., May 8, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the launch of its new Dream Makers Miracle Fund for stomach cancer patients and their families.

Key Points: 
  • PLANTATION,Fla., May 8, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the launch of its new Dream Makers Miracle Fund for stomach cancer patients and their families.
  • The initiative, which is part of DDF's Patient Resource Education Program, aims to spread joy within the stomach cancer community by providing patients and their families with bucket-list inspired experiences.
  • More information and updates about the Dream Makers Miracle Fund and its application process will be made available on DDF's website.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide and the lack of federal funding for stomach cancer research.

truSculpt® flex From Cutera, Inc. Wins 2020 Good Housekeeping Award

Monday, May 4, 2020 - 12:05pm

BRISBANE, Calif., May 4, 2020 /PRNewswire/ -- CUTERA, INC. , (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, proudly announces that truSculpt flex is a Good Housekeeping2020 Beauty Award Winner for Ultimate Body Product.

Key Points: 
  • BRISBANE, Calif., May 4, 2020 /PRNewswire/ -- CUTERA, INC. , (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, proudly announces that truSculpt flex is a Good Housekeeping2020 Beauty Award Winner for Ultimate Body Product.
  • The non-invasive, no-downtime treatment builds noticeable strength and visible toning results in 45 minutes with as little as four treatments.
  • The muscle sculpting technology underwent rigorous testing by Good Housekeeping's seasoned team of experts, earning the honor of Ultimate Body Product in the professional treatment category.
  • truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen.

Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

Tuesday, April 28, 2020 - 9:30pm

The dial-in information for the call is as follows:

Key Points: 
  • The dial-in information for the call is as follows:
    Participants are asked to dial in 15 minutes before the start of the call to register.
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
  • The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
  • For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .

Biomerica Announces Third Quarter Financial Results

Wednesday, April 15, 2020 - 1:30pm

The quarter ended February 29, 2020 included a $157,939 non-cash stock option related expense.

Key Points: 
  • The quarter ended February 29, 2020 included a $157,939 non-cash stock option related expense.
  • Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development.
  • The Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods (e.g.
  • Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica.

InventHelp Inventor Develops Novel Food Bolus Disimpaction Device (DHM-513)

Thursday, April 9, 2020 - 3:00pm

PITTSBURGH, April 9, 2020 /PRNewswire/ -- An inventor from Holly Springs, N.C., has developed the patent pending ESOPHAGUS FOOD DISIMPACTOR, a novel device and technique that can be used to disimpact food from the esophagus at the chest or throat level.

Key Points: 
  • PITTSBURGH, April 9, 2020 /PRNewswire/ -- An inventor from Holly Springs, N.C., has developed the patent pending ESOPHAGUS FOOD DISIMPACTOR, a novel device and technique that can be used to disimpact food from the esophagus at the chest or throat level.
  • "I am a gastroenterologist and have had to remove food blockages many times over my 28 years of practicing.
  • I have devised an easier way to do this," said the inventor.
  • The ESOPHAGUS FOOD DISIMPACTOR provides an improved method of removing impacted food from the esophagus.

Worldwide Gastrointestinal Partnering Deals Collection 2014-2024: Comprehensive Access to 390+ Gastrointestinal Deal Records

Wednesday, April 8, 2020 - 6:45pm

Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Key Points: 
  • Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
  • Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014.
  • In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014.